Maintenance therapy for recurrent or metastatic nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding a new drug (BL-B01D1) to an immunotherapy maintenance treatment can help keep nasopharyngeal cancer from growing after initial chemotherapy. It aims to improve how long patients live without the cancer progressing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have nasopharyngeal cancer that has come back or spread to other parts of the body.
- You have not had any previous systemic treatment (like chemotherapy or immunotherapy) for this cancer.
- You have at least one tumor that can be measured on scans.
- You are generally well enough to care for yourself (ECOG score 0 or 1).
- Your heart, kidneys, liver, and other organs are working well enough to receive the study treatment.
- You have not had certain prior treatments, including antibody-drug conjugates or drugs targeting EGFR or HER3.
- You do not have active autoimmune diseases, severe infections, or other serious medical conditions that could interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
This study tests a new drug called BL-M08D1 for people with nasopharyngeal cancer or other solid tumors that have returned or spread. The trial is in early phases to see how safe the drug is and whether it can shrink tumors.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.